A melioidosis subunit vaccine combining CPS-CRM197 and His-tagless Hcp1 with Alhydrogel plus CpG was evaluated in cynomolgus macaques. It induced CPS-specific IgG, opsonizing antibodies, Hcp1-specific IgG and measurable IFN-gamma T-cell responses. Three doses were well tolerated with no reported adverse events, and antigen production was designed to be GMP-compatible. This supports clinical development but does not yet demonstrate protection in humans.
Key findings
- The vaccine elicited antibody and measurable T-cell responses. • No adverse events were reported after three doses in macaques. • Antigen production was designed for GMP-compatible advancement.
Why this matters globally
For a severe tropical disease without a routinely available vaccine, this work helps bridge small-animal research and human trials, while efficacy and clinical safety remain to be established.
Thai researcher contribution
Narisara Chantratita and the Mahidol–Oxford Tropical Medicine network bring endemic-region Burkholderia expertise to vaccine development.
Limitations to consider
The abstract does not state animal numbers and reports no pathogen-challenge efficacy test; absence of adverse events in a small primate study cannot guarantee human safety.